{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T16:36:37Z","timestamp":1778085397437,"version":"3.51.4"},"reference-count":50,"publisher":"e-Century Publishing Corporation","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/kjgs9928","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T04:18:36Z","timestamp":1732853916000},"page":"6365-6383","source":"Crossref","is-referenced-by-count":2,"title":["Contemplating the prognostic and therapeutic potential of CD19: a comprehensive analysis across diverse cancer types"],"prefix":"10.62347","volume":"16","author":[{"given":"Xiuhui","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/cm9.0000000000002626","article-title":"Global burden prediction of gastric cancer during demographic transition from 2020 to 2040","volume":"136","author":"Yan","year":"2023","unstructured":"Yan C, Shan F, Ying X and Li Z. Global burden prediction of gastric cancer during demographic transition from 2020 to 2040. Chin Med J (Engl) 2023; 136: 397-406.","journal-title":"Chin Med J (Engl)"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00109-020-01874-2","article-title":"Clinical implications of intratumor heterogeneity: challenges and opportunities","volume":"98","author":"Ram&#xF3","year":"2020","unstructured":"Ramón y Cajal S, Sesé M, Capdevila C, Aasen T, De Mattos-Arruda L, Diaz-Cano SJ, Hernández-Losa J and Castellví J. Clinical implications of intratumor heterogeneity: challenges and opportunities. J Mol Med (Berl) 2020; 98: 161-177.","journal-title":"J Mol Med (Berl)"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/bfgp\/elac017","article-title":"Multiomics technologies: role in disease biomarker discoveries and therapeutics","volume":"22","author":"Dar","year":"2023","unstructured":"Dar MA, Arafah A, Bhat KA, Khan A, Khan MS, Ali A, Ahmad SM, Rashid SM and Rehman MU. Multiomics technologies: role in disease biomarker discoveries and therapeutics. Brief Funct Genomics 2023; 22: 76-96.","journal-title":"Brief Funct Genomics"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.3390\/cancers15133474","article-title":"Advances in genomic data and biomarkers: revolutionizing NSCLC diagnosis and treatment","volume":"15","author":"JC","year":"2023","unstructured":"Restrepo JC, Dueñas D, Corredor Z and Liscano Y. Advances in genomic data and biomarkers: revolutionizing NSCLC diagnosis and treatment. Cancers (Basel) 2023; 15: 3474.","journal-title":"Cancers (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.it.2023.06.004","article-title":"Glycome dynamics in T and B cell development: basic immunological mechanisms and clinical applications","volume":"44","author":"Vicente","year":"2023","unstructured":"Vicente MM, Leite-Gomes E and Pinho SS. Glycome dynamics in T and B cell development: basic immunological mechanisms and clinical applications. Trends Immunol 2023; 44: 585-597.","journal-title":"Trends Immunol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1002\/pbc.25462","article-title":"CD19: a multifunctional immunological target molecule and its implications for Blineage acute lymphoblastic leukemia","volume":"62","author":"Weiland","year":"2015","unstructured":"Weiland J, Elder A, Forster V, Heidenreich O, Koschmieder S and Vormoor J. CD19: a multifunctional immunological target molecule and its implications for Blineage acute lymphoblastic leukemia. Pediatr Blood Cancer 2015; 62: 1144-1148.","journal-title":"Pediatr Blood Cancer"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.imlet.2023.05.005","article-title":"Addressing the key issue: antigen-specific targeting of B cells in autoimmune diseases","volume":"259","author":"Holborough-Kerkvliet","year":"2023","unstructured":"Holborough-Kerkvliet MD, Kroos S, van de Wetering R and Toes REM. Addressing the key issue: antigen-specific targeting of B cells in autoimmune diseases. Immunol Lett 2023; 259: 37-45.","journal-title":"Immunol Lett"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"837457","DOI":"10.3389\/fimmu.2022.837457","article-title":"CD19-targeted immunotherapies for diffuse large B-cell lymphoma","volume":"13","author":"Gambella","year":"2022","unstructured":"Gambella M, Carlomagno S, Raiola AM, Giannoni L, Ghiggi C, Setti C, Giordano C, Luchetti S, Serio A, Bo A, Falco M, Della Chiesa M, Angelucci E and Sivori S. CD19-targeted immunotherapies for diffuse large B-cell lymphoma. Front Immunol 2022; 13: 837457.","journal-title":"Front Immunol"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Raufi A, Ebrahim AS and Al-Katib A. Targeting CD19 in B-cell lymphoma: emerging role of SAR3419. Cancer Manag Res 2013; 5: 225-233.","DOI":"10.2147\/CMAR.S45957"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3892\/mco.2023.2691","article-title":"Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy","volume":"19","author":"Poojary","year":"2023","unstructured":"Poojary R, Song AF, Song BS, Song CS, Wang L and Song J. Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy. Mol Clin Oncol 2023; 19: 95.","journal-title":"Mol Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41417-018-0073-7","article-title":"Autologous CD19-directed chimeric antigen receptor-T cell is an effective and safe treatment to refractory or relapsed diffuse large B-cell lymphoma","volume":"26","author":"Bao","year":"2019","unstructured":"Bao F, Wan W, He T, Qi F, Liu G, Hu K, Lu XA, Yang P, Dong F, Wang J and Jing H. Autologous CD19-directed chimeric antigen receptor-T cell is an effective and safe treatment to refractory or relapsed diffuse large B-cell lymphoma. Cancer Gene Ther 2019; 26: 248-255.","journal-title":"Cancer Gene Ther"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Sworder BJ, Kurtz DM, Alig SK, Frank MJ, Shukla N, Garofalo A, Macaulay CW, Shahrokh Esfahani M, Olsen MN, Hamilton J, Hosoya H, Hamilton M, Spiegel JY, Baird JH, Sugio T, Carleton M, Craig AFM, Younes SF, Sahaf B, Sheybani ND, Schroers-Martin JG, Liu CL, Oak JS, Jin MC, Beygi S, Hüttmann A, Hanoun C, Dührsen U, Westin JR, Khodadoust MS, Natkunam Y, Majzner RG, Mackall CL, Diehn M, Miklos DB and Alizadeh AA. Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas. Cancer Cell 2023; 41: 210-225, e215.","DOI":"10.1016\/j.ccell.2022.12.005"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s12967-023-04292-3","article-title":"Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments","volume":"21","author":"Dagar","year":"2023","unstructured":"Dagar G, Gupta A, Masoodi T, Nisar S, Merhi M, Hashem S, Chauhan R, Dagar M, Mirza S, Bagga P, Kumar R, Akil ASA, Macha MA, Haris M, Uddin S, Singh M and Bhat AA. Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments. J Transl Med 2023; 21: 449.","journal-title":"J Transl Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1177\/10815589231191811","article-title":"Novel chimeric antigen receptor targets and constructs for acute lymphoblastic leukemia: moving beyond CD19","volume":"72","author":"Acharya","year":"2024","unstructured":"Acharya L, Garg A, Rai M, Kshetri R, Grewal US and Dhakal P. Novel chimeric antigen receptor targets and constructs for acute lymphoblastic leukemia: moving beyond CD19. J Investig Med 2024; 72: 32-46.","journal-title":"J Investig Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1168622","DOI":"10.3389\/fonc.2023.1168622","article-title":"T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and future directions","volume":"13","author":"Russler-Germain","year":"2023","unstructured":"Russler-Germain DA and Ghobadi A. T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and future directions. Front Oncol 2023; 13: 1168622.","journal-title":"Front Oncol"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, Li B and Liu XS. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res 2020; 48: W509-W514.","DOI":"10.1093\/nar\/gkaa407"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.neo.2017.05.002","article-title":"UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses","volume":"19","author":"Chandrashekar","year":"2017","unstructured":"Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and Varambally S. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia 2017; 19: 649-658.","journal-title":"Neoplasia"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Lánczky A and Győrffy B. Web-based survival analysis tool tailored for medical research (KMplot): development and implementation. J Med Internet Res 2021; 23: e27633.","DOI":"10.2196\/27633"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Tang Z, Kang B, Li C, Chen T and Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res 2019; 47: W556-W560.","DOI":"10.1093\/nar\/gkz430"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/pro.3307","article-title":"The human protein atlas: a spatial map of the human proteome","volume":"27","author":"Thul","year":"2018","unstructured":"Thul PJ and Lindskog C. The human protein atlas: a spatial map of the human proteome. Protein Sci 2018; 27: 233-244.","journal-title":"Protein Sci"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Liu CJ, Hu FF, Xie GY, Miao YR, Li XW, Zeng Y and Guo AY. GSCA: an integrated platform for gene set cancer analysis at genomic, pharmacogenomic and immunogenomic levels. Brief Bioinform 2023; 24: bbac558.","DOI":"10.1093\/bib\/bbac558"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C and Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2: 401-404.","journal-title":"Cancer Discov"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1093\/bioinformatics\/btz210","article-title":"TISIDB: an integrated repository portal for tumor-immune system interactions","volume":"35","author":"Ru","year":"2019","unstructured":"Ru B, Wong CN, Tong Y, Zhong JY, Zhong SSW, Wu WC, Chu KC, Wong CY, Lau CY, Chen I, Chan NW and Zhang J. TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics 2019; 35: 4200-4202.","journal-title":"Bioinformatics"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, Jensen LJ and Mering CV. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res 2019; 47: D607-D613.","DOI":"10.1093\/nar\/gky1131"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Sherman BT, Hao M, Qiu J, Jiao X, Baseler MW, Lane HC, Imamichi T and Chang W. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res 2022; 50: W216-W221.","DOI":"10.1093\/nar\/gkac194"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Roy M, Biswas J and Datta A. Genetics and epigenetics of breast cancer. Springer; 2023.","DOI":"10.1007\/978-981-19-9925-3"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.3332\/ecancer.2020.1107","article-title":"Does human papillomavirus cause human colorectal cancer? Applying Bradford Hill criteria postulates","volume":"14","author":"Usman","year":"2020","unstructured":"Usman M, Hameed Y and Ahmad M. Does human papillomavirus cause human colorectal cancer? Applying Bradford Hill criteria postulates. Ecancermedicalscience 2020; 14: 1107.","journal-title":"Ecancermedicalscience"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"819","DOI":"10.32604\/or.2023.029414","article-title":"Elucidating the clinical and immunological value of m6A regulator-mediated methylation modification patterns in adrenocortical carcinoma","volume":"31","author":"Xu","year":"2023","unstructured":"Xu W, Li H, Hameed Y, Abdel-Maksoud MA, Almutairi SM, Mubarak A, Aufy M, Alturaiki W, Alshalani AJ, Mahmoud AM and Li C. Elucidating the clinical and immunological value of m6A regulator-mediated methylation modification patterns in adrenocortical carcinoma. Oncol Res 2023; 31: 819-831.","journal-title":"Oncol Res"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"432","DOI":"10.62347\/WSEF7878","article-title":"CDCA8, a mitosis-related gene, as a prospective pan-cancer biomarker: implications for survival prognosis and oncogenic immunology","volume":"16","author":"Hu","year":"2024","unstructured":"Hu H, Umair M, Khan SA, Sani AI, Iqbal S, Khalid F, Sultan R, Abdel-Maksoud MA, Mubarak A, Dawoud TM, Malik A, Saleh IA, Al Amri AA, Algarzae NK, Kodous AS and Hameed Y. CDCA8, a mitosis-related gene, as a prospective pan-cancer biomarker: implications for survival prognosis and oncogenic immunology. Am J Transl Res 2024; 16: 432-445.","journal-title":"Am J Transl Res"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"12690","DOI":"10.3390\/ijms241612690","article-title":"Omics technologies improving breast cancer research and diagnostics","volume":"24","author":"Orsini","year":"2023","unstructured":"Orsini A, Diquigiovanni C and Bonora E. Omics technologies improving breast cancer research and diagnostics. Int J Mol Sci 2023; 24: 12690.","journal-title":"Int J Mol Sci"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"106674","DOI":"10.1016\/j.phrs.2023.106674","article-title":"Biomarker discovery and application-an opportunity to resolve the challenge of liver cancer diagnosis and treatment","volume":"189","author":"Chen","year":"2023","unstructured":"Chen J, Niu C, Yang N, Liu C, Zou SS and Zhu S. Biomarker discovery and application-an opportunity to resolve the challenge of liver cancer diagnosis and treatment. Pharmacol Res 2023; 189: 106674.","journal-title":"Pharmacol Res"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"63","DOI":"10.62347\/TWOY1681","article-title":"Unlocking the diagnostic, prognostic roles, and immune implications of BAX gene expression in pan-cancer analysis","volume":"16","author":"Abdel-Maksoud","year":"2024","unstructured":"Abdel-Maksoud MA, Ullah S, Nadeem A, Shaikh A, Zia MK, Zakri AM, Almanaa TN, Alfuraydi AA, Mubarak A and Hameed Y. Unlocking the diagnostic, prognostic roles, and immune implications of BAX gene expression in pan-cancer analysis. Am J Transl Res 2024; 16: 63-74.","journal-title":"Am J Transl Res"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"107457","DOI":"10.1016\/j.compbiolchem.2021.107457","article-title":"Integrative analysis of multi-omics data highlighted TP53 as a potential diagnostic and prognostic biomarker of survival in breast invasive carcinoma patients","volume":"92","author":"Hameed","year":"2021","unstructured":"Hameed Y and Ejaz S. Integrative analysis of multi-omics data highlighted TP53 as a potential diagnostic and prognostic biomarker of survival in breast invasive carcinoma patients. Comput Biol Chem 2021; 92: 107457.","journal-title":"Comput Biol Chem"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1110028","DOI":"10.3389\/fimmu.2023.1110028","article-title":"Predictive short\/long-term efficacy biomarkers and resistance mechanisms of CD19-directed CAR-T immunotherapy in relapsed\/refractory B-cell lymphomas","volume":"14","author":"Xu","year":"2023","unstructured":"Xu H, Li N, Wang G and Cao Y. Predictive short\/long-term efficacy biomarkers and resistance mechanisms of CD19-directed CAR-T immunotherapy in relapsed\/refractory B-cell lymphomas. Front Immunol 2023; 14: 1110028.","journal-title":"Front Immunol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/14737159.2018.1448269","article-title":"The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker","volume":"18","author":"Sanchez","year":"2018","unstructured":"Sanchez E, Tanenbaum EJ, Patil S, Li M, Soof CM, Vidisheva A, Waterman GN, Hekmati T, Tang G, Wang CS, Chen H and Berenson J. The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker. Expert Rev Mol Diagn 2018; 18: 319-329.","journal-title":"Expert Rev Mol Diagn"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"7844","DOI":"10.1002\/cam4.5551","article-title":"Chimeric antigen receptor T (CAR-T) cells: novel cell therapy for hematologi cal malignancies","volume":"12","author":"Abbasi","year":"2023","unstructured":"Abbasi S, Totmaj MA, Abbasi M, Hajazimian S, Goleij P, Behroozi J, Shademan B, Isazadeh A and Baradaran B. Chimeric antigen receptor T (CAR-T) cells: novel cell therapy for hematologi cal malignancies. Cancer Med 2023; 12: 7844-7858.","journal-title":"Cancer Med"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Savoldo B, Grover N and Dotti G. CAR T cells for hematological malignancies. J Clin Invest 2024; 134: e177160.","DOI":"10.1172\/JCI177160"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1517\/21678707.2015.1062753","article-title":"Therapeutic targets and investigated strategies for treating B-cell non-Hodgkin lymphoma","volume":"3","author":"Villasboas","year":"2015","unstructured":"Villasboas JC and Ansell SM. Therapeutic targets and investigated strategies for treating B-cell non-Hodgkin lymphoma. Expert Opinion on Orphan Drugs 2015; 3: 921-932.","journal-title":"Expert Opinion on Orphan Drugs"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"31","DOI":"10.21037\/aol.2017.10.02","article-title":"Chimeric antigen receptor T cells for the treatment of lymphoma","volume":"1","author":"Purev","year":"2017","unstructured":"Purev E and Fry TJ. Chimeric antigen receptor T cells for the treatment of lymphoma. Ann Lymphoma 2017; 1: 31-42.","journal-title":"Ann Lymphoma"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1113882","DOI":"10.3389\/fimmu.2023.1113882","article-title":"The current landscape of CAR T-cell therapy for solid tumors: mechanisms, research progress, challenges, and counterstrategies","volume":"14","author":"Daei Sorkhabi","year":"2023","unstructured":"Daei Sorkhabi A, Mohamed Khosroshahi L, Sarkesh A, Mardi A, Aghebati-Maleki A, Aghebati-Maleki L and Baradaran B. The current landscape of CAR T-cell therapy for solid tumors: mechanisms, research progress, challenges, and counterstrategies. Front Immunol 2023; 14: 1113882.","journal-title":"Front Immunol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","article-title":"CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment","volume":"10","author":"Martinez","year":"2019","unstructured":"Martinez M and Moon EK. CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front Immunol 2019; 10: 128.","journal-title":"Front Immunol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41423-021-00655-2","article-title":"Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment","volume":"18","author":"Liu","year":"2021","unstructured":"Liu G, Rui W, Zhao X and Lin X. Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment. Cell Mol Immunol 2021; 18: 1085-1095.","journal-title":"Cell Mol Immunol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1136\/jcp.51.5.364","article-title":"Levels of expression of CD19 and CD20 in chronic B cell leukaemias","volume":"51","author":"Ginaldi","year":"1998","unstructured":"Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R and Catovsky D. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol 1998; 51: 364-369.","journal-title":"J Clin Pathol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/nrclinonc.2013.46","article-title":"Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors","volume":"10","author":"Kochenderfer","year":"2013","unstructured":"Kochenderfer JN and Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol 2013; 10: 267-276.","journal-title":"Nat Rev Clin Oncol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.3390\/cancers15092531","article-title":"CD19 (+) B cell combined with prognostic nutritional index predicts the clinical outcomes of patients with gastric cancer who underwent surgery","volume":"15","author":"Sun","year":"2023","unstructured":"Sun H, Wang H, Pan H, Zuo Y, Zhao R, Huang R, Xue Y and Song H. CD19 (+) B cell combined with prognostic nutritional index predicts the clinical outcomes of patients with gastric cancer who underwent surgery. Cancers (Basel) 2023; 15: 2531.","journal-title":"Cancers (Basel)"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1182\/blood.V77.10.2242.2242","article-title":"Prognostic value of lymphocyte surface markers in acute myeloid leukemia","volume":"77","author":"Ball","year":"1991","unstructured":"Ball ED, Davis RB, Griffin JD, Mayer RJ, Davey FR, Arthur DC, Wurster-Hill D, Noll W, Elghetany MT, Allen SL, et al. Prognostic value of lymphocyte surface markers in acute myeloid leukemia. Blood 1991; 77: 2242-50.","journal-title":"Blood"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"23293899","DOI":"10.1101\/2023.08.09.23293899","article-title":"Integrating genome and epigenome data to identify tissue-specific DNA methylation biomarkers for cancer risk","volume":"2023","author":"Yang","year":"2023","unstructured":"Yang Y, Chen Y, Xu S, Guo X, Jia G, Ping J, Shu X, Zhao T, Yuan F and Wang G. Integrating genome and epigenome data to identify tissue-specific DNA methylation biomarkers for cancer risk. medRxiv 2023; 2023: 23293899.","journal-title":"medRxiv"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/gcc.22154","article-title":"Genistein inhibits DNA methylation and increases expression of tumor suppressor genes in human breast cancer cells","volume":"53","author":"Xie","year":"2014","unstructured":"Xie Q, Bai Q, Zou LY, Zhang QY, Zhou Y, Chang H, Yi L, Zhu JD and Mi MT. Genistein inhibits DNA methylation and increases expression of tumor suppressor genes in human breast cancer cells. Genes Chromosomes Cancer 2014; 53: 422-431.","journal-title":"Genes Chromosomes Cancer"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"517","DOI":"10.3389\/fonc.2019.00517","article-title":"Wwox deletion in mouse B cells leads to genomic instability, neoplastic transformation, and monoclonal gammopathies","volume":"9","author":"McBride","year":"2019","unstructured":"McBride KM, Kil H, Mu Y, Plummer JB, Lee J, Zelazowski MJ, Sebastian M, Abba MC and Aldaz CM. Wwox deletion in mouse B cells leads to genomic instability, neoplastic transformation, and monoclonal gammopathies. Front Oncol 2019; 9: 517.","journal-title":"Front Oncol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/onc.2015.88","article-title":"Mdm2 overexpression and p73 loss exacerbate genomic instability and dampen apoptosis, resulting in B-cell lymphoma","volume":"35","author":"Riley","year":"2016","unstructured":"Riley MF, You MJ, Multani AS and Lozano G. Mdm2 overexpression and p73 loss exacerbate genomic instability and dampen apoptosis, resulting in B-cell lymphoma. Oncogene 2016; 35: 358-365.","journal-title":"Oncogene"}],"container-title":["American Journal of Translational Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajtr\/16\/11\/ajtr0156590.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:56:50Z","timestamp":1766023010000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/16\/11\/ajtr0156590.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":50,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.62347\/kjgs9928","relation":{},"ISSN":["1943-8141"],"issn-type":[{"value":"1943-8141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]}}}